Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • Evogliptin and...

Evogliptin and metformin combo effective for type 2 diabetes treatment: JAPI

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-02-04T15:15:59+05:30  |  Updated On 3 Oct 2023 2:28 PM IST
Evogliptin and metformin combo effective for type 2 diabetes treatment: JAPI
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Mumbai, Maharashtra: Combination therapy of Evogliptin and Metformin could be a promising treatment strategy for type 2 diabetes (T2D), finds a recent study in the Journal of the Association of Physicians of India. According to the study, the combo exerts a complementary glucose-lowering effect and is well-tolerated option for patients requiring therapy for type 2 diabetes.

Achieving adequate blood sugar control remains a difficult but achievable goal in T2D patients. Oral antidiabetic agents (OADs) are important option for T2D management. For adequate glycemic control, most T2D patients require more than one medications. Metformin based combination therapy is recommended for patients in whom monotherapy is not sufficient.

Evogliptin, a recently developed dipeptidyl peptidase-4 (DPP-4) inhibitor, can be combined with metformin for T2D treatment. Combination therapy of Evogliptin and Metformin lowers blood sugar levels by augmenting insulin secretion, suppressing glucagon secretion and insulin sensitization. There was no clinically relevant pharmacokinetic differences between the combo (of Evogliptin and Metformin) and the administration of each drug alone as a monotherapy. Also, compared to the respective monotherapies, the combo also provides significantly better glycemic control.

Several multicentre randomized clinical trials conducted in various countries like South Korea, Russia and India have demonstrated safety and efficacy of Evogliptin and Metformin. Consequently, fixed dose combination (FDC) of Evogliptin and Metformin is approved in South Korea and India. Polypharmacy and complexity of the treatment regimen are well known factors of poor medication adherence and FDCs have the potential to improve adherence by reducing the pill burden.

Adopting this combo in clinical practice for T2D management will help in achieving a greater degree of HbA1c reduction than that observed with the use of either drug as monotherapy, and is unlikely to cause significant hypoglycemia.

"Combination therapy of Evogliptin and Metformin is a promising strategy in the treatment of T2DM," concluded Akhilesh Sharma, President and CMO Medical Department of Alkem Laboratory, Mumbai, Maharashtra, and colleagues.

Evogliptin combination with Metformin

For over 50 years, metformin has been the most common first-line treatment for T2DM worldwide. Metformin primarily reduces hepatic glucose production, intestinal glucose absorption, and increase insulin sensitivity (improved peripheral glucose uptake and utilization). This effect increases insulin sensitivity in subjects with insulin resistance. Evolving evidence suggests that treatment with metformin is associated with reduction in all-cause mortality, even in overweight subjects with T2DM.

Evogliptin is a newly developed DPP-4 inhibitor for the treatment of T2DM, which increases GLP-1 and GIP, thus inhibits glucagon release, which in turn increases insulin secretion, decreasing gastric emptying, and thereby controlling blood glucose levels. In a first-in-human study, Evogliptin was well tolerated and showed dose proportional pharmacokinetics (doses between 1.25 and 60 mg) with a long half-life (30 hours) after a single administration. In terms of efficacy, monotherapy with Evogliptin (5 mg dose daily for 12 weeks) significantly reduced the mean HbA1c by 0.66%, and improved oral glucose tolerance test (OGTT) results and β-cell function compared to the placebo in subjects with type 2 DM who exhibited inadequate glycaemic control with diet and exercise alone.

Evogliptin is expected to be used as the add-on agent to metformin; therefore, the fixed-dose combination (FDC) formulation of evogliptin and metformin might increase therapeutic success by improving medication adherence compared with taking two individual component tablets. Indeed, the use of FDC formulations of two or more therapeutic agents with complementary mechanisms of action has been increasing in the clinical setting, and studies have shown that FDCs are more effective than concomitant administration of individual components.

The study titled, "Clinical Evidence of Evogliptin plus Metformin in Management of Type 2 Diabetes mellitus," is published in the Journal of the Association of Physicians of India.

DOI: https://www.japi.org/x274b474/clinical-evidence-of-evogliptin-plus-metformin-in-management-of-type-2-diabetes-mellitus

JAPIEvogliptinmetformintype 2 diabetes
Source : Journal of the Association of Physicians of India
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Identifying Candidates for Aspirin in Primary Prevention: Men Aged 40-50 with Hypertension, Dyslipidemia, and Familial ASCVD Risk

    Identifying Candidates for Aspirin in Primary Prevention: Men Aged 40-50 with Hypertension,...

    Featured image representing thinking

    Is Pharma Marketing Going Through "Thinking Recession"?

    Beyond BMI: Why Pioglitazone Deserves a Place in Managing Thin-Fat Type 2 Diabetes in India

    Beyond BMI: Why Pioglitazone Deserves a Place in Managing 'Thin-Fat' Type 2 Diabetes in India

    How to Improve Adherence in Hypertensive Patients? Bridging the Gap with CONNECT Tool

    How to Improve Adherence in Hypertensive Patients? Bridging the Gap with CONNECT Tool

    Vestibular Migraine: Clinical Update and Role of Buccal Prochlorperazine

    Vestibular Migraine: Clinical Update and Role of Buccal Prochlorperazine

    View All

    Journal Club Today

    Role of Sunscreen in Children Dr. Tarun Anand Explains

    Role of Sunscreen in Children Dr. Tarun Anand Explains

    View All

    Health News Today

    Health Bulletin 1/July/ 2025

    Health Bulletin 1/July/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok